Customary indemnification agreements with the directors and executive officers of Humacyte following the Merger.
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Laura E. Niklason
Also a director
President, Chief Executive Officer and Director
|
63 | Not stated | $5,234,908 | |
|
Dale A. Sander
CFO and Chief Corp. Dev. Off
Title from the Form 4 dated May 18, 2026
|
66 | Not stated | $2,131,658 | |
|
Shamik J. Parikh
Chief Medical Officer
|
53 |
Since 2022
4 years
|
$2,096,556 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Sep 28, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Kathleen Sebelius
Board chair
|
77 |
2021
5 years
|
Independent |
Audit Committee
|
Devoted Health, Inc., Included Health Inc., Exact Sciences Corporation | $227,800 | |
|
Laura E. Niklason
CEO
|
63 |
2021
5 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
John P. Bamforth
|
62 |
2024
2 years
|
Independent |
Commercial Committee
|
None stated | $202,800 | |
|
Keith Anthony Jones
|
65 |
2024
2 years
|
Independent | None stated | None stated | $202,800 | |
|
Emery N. Brown
|
69 |
2021
5 years
|
Independent |
Nominating and Governance Committee
|
None stated | $202,800 | |
|
Michael T. Constantino
|
63 |
2021
5 years
|
Independent |
Audit Committee · Chair
|
None stated | $210,300 | |
|
Brady W. Dougan
|
66 |
2021
5 years
|
Not independent | None stated | None stated | $202,800 | |
|
C. Bruce Green
|
70 |
2022
4 years
|
Independent |
Nominating and Governance Committee
|
None stated | $202,800 | |
|
Diane Seimetz
|
55 |
2022
4 years
|
Independent | None stated | Cumulus Oncology, GlycanAGE, Temedica, mbiomics | $202,800 | |
|
Max Wallace
|
74 |
2021
5 years
|
Not stated |
Nominating and Governance Committee · Chair
|
None stated | $207,800 | |
|
Susan Windham-Bannister
|
74 |
2021
5 years
|
Not stated |
Commercial Committee · Chair
|
Aridis Pharmaceuticals, Inc. | $207,800 | |
|
Scott Coward
Joined Sep 22, 2026
|
- | - | - |
Audit Committee
|
- | - | |
|
Paul Kuznik
Joined Sep 22, 2026
|
- | - | - |
Commercial Committee
|
- | - | |
|
Todd M. Pope
Leaving at the meeting
|
60 |
2021
5 years
|
Independent |
Compensation Committee · Chair
|
None stated | $207,800 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Customary indemnification agreements with the directors and executive officers of Humacyte following the Merger.
Services agreements (May 2022 and June 2023) for a study of outcomes of dialysis patients; company paid for clinical research services performed under them.
Master services agreement (June 2024) under which Frenova performs clinical research services for the V012 Phase 3 clinical trial.
Service agreement (July 2024) under which Frenova conducts a study of hemodialysis patient data in certain European countries; company paid for services in 2023.
Distribution agreement (June 2018, as amended) giving Fresenius Medical Care a right to receive a royalty on sales of the ATEV distribution product.
Three license agreements, two still in effect; Legacy Humacyte has made payments of license fees and other expenses to Yale.
Loading...